EC Number   |
Inhibitors |
Structure  |
|---|
   3.4.17.23 | more |
no inhibition by lisinopril |
 |
| 3.4.17.23 | more |
no inhibition by captopril |
|
| 3.4.17.23 | more |
no inhibition by enalaprilat |
|
| 3.4.17.23 | more |
rampiril does not influence the mRNA content in renal tubules |
|
| 3.4.17.23 | more |
no inhibition by lisinopril, no inhibition by captopril, no inhibition by enalaprilat |
|
| 3.4.17.23 | more |
construction of 6 constrained peptide libraries, selected from peptide libraries displayed on phage, peptides, 21-27 amino acids, with inhibitory effects on the enzyme, specificity and stability, selection of inhibitory sequence motifs, best CXPXRXXPWXXC, overview |
|
| 3.4.17.23 | more |
carboxylalkyl compounds cilazaprilat, indolaprilat, perindoprilat, quinaprilat and spiraprilat, the thiol compounds rentiapril and zofenapril, and the phosphoryl compounds ceranopril and fosinoprilat fail to inhibit the hydrolysis of either angiotensin I or angiotensin II by ACE2 at concentrations that abolished activity of EC 3.4.15.1 |
|
| 3.4.17.23 | more |
ACE-2 mRNA and activity are severely downregulated in lung fibrosis |
|
| 3.4.17.23 | more |
not inhibited by captopri and lisinopril |
|
| 3.4.17.23 | more |
the Spike protein of the SARS-coronavirus reduces ACE2 expression |
|
